Safety of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis (Hlh): Relationship to treatment Exposure

被引：0
|
作者：
Jordan, Michael [1 ,2 ,3 ,4 ]
Locatelli, Franco [5 ,6 ]
Jacqmin, Philippe [7 ]
Laveille, Christian [8 ]
Snoeck, Eric [9 ]
de Min, Cristina [10 ]
机构：
[1] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Immunobiol, Cincinnati, OH 45229 USA
[2] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Bone Marrow Transplantat, Cincinnati, OH 45229 USA
[3] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Immune Deficiency, Cincinnati, OH 45229 USA
[4] Univ Cincinnati, Coll Med, Cincinnati, OH USA
[5] Sapienza Univ Rome, Dept Pediat, Rome, Italy
[6] IRCCS Bambino Gesu Childrens Hosp, Dept Pediat Hematol Oncol & Cell & Gene Therapy, Rome, Italy
[7] MnS Modelling & Simulat, Dinant, Belgium
[8] Calvagone Sarl, Liergues, France
[9] Luccio BV, Meerhout, Belgium
[10] Swedish Orphan Biovitrum AG Sobi, Basel, Switzerland
来源：
PEDIATRIC BLOOD & CANCER | 2022年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S11 / S11
页数：1
相关论文
共 50 条
  • [21] PEDIATRIC REFRACTORY SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS SUCCESSFULLY TREATED WITH EMAPALUMAB
    Galipp, K. M.
    Beg, K. A.
    Welliver, R.
    Baker, A.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2021, 69 (02) : 617 - 618
  • [22] POST-HSCT OUTCOMES AFTER EMAPALUMAB TREATMENT IN PRIMARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
    Jordan, Michael
    Merli, Pietro
    Allen, Carl
    Cesaro, Simone
    Rizzari, Carmello
    Rao, Anupama
    Degar, Barbara
    Garrington, Timothy
    Sevilla, Julian
    Putti, Maria Caterina
    Fragoli, Franco
    Ahlmann, Martina
    Dapena, Jose-Luis
    Henry, Michael
    Grom, Alexei
    Locatelli, Franco
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S62 - S62
  • [23] Real-World treatment Patterns and Outcomes in Patients with Hemophagocytic Lymphohistiocytosis (Hlh) and other Clinical Conditions Treated with Emapalumab: The Real-Hlh study Design
    Oladapo, Abiola
    Allen, Carl
    Leiding, Jennifer
    Chandrakasan, Shanmuganathan
    Walkovich, Kelly J.
    Oladapo, Abiola
    Yee, John
    Pednekar, Priti
    Raza, Sajjad
    Jordan, Michael
    PEDIATRIC BLOOD & CANCER, 2022, 69 : S18 - S19
  • [24] Real-World Treatment Patterns and Outcomes in Patients with Hemophagocytic Lymphohistiocytosis (HLH) and Other Clinical Conditions Treated with Emapalumab: The Real-HLH Study Design
    Allen, Carl E.
    Leiding, Jennifer
    Chandrakasan, Shanmuganathan
    Walkovich, Kelly J.
    Oladapo, Abiola
    Yee, John
    Pednekar, Priti
    Raza, Sajjad
    Jordan, Michael B.
    BLOOD, 2021, 138
  • [25] Real-World Treatment Patterns and Outcomes Among Patients with Primary Hemophagocytic Lymphohistiocytosis with and without Infection at Diagnosis and Treated with Emapalumab: The Real-HLH Study
    Allen, Carl E.
    Chandrakasan, Shanmuganathan
    Jordan, Michael B.
    Leiding, Jennifer W.
    Oladapo, Abiola
    Pednekar, Priti
    Walkovich, Kelly
    Yee, John
    BLOOD, 2023, 142
  • [26] Real-World Demographics, Clinical Characteristics, and Treatment Patterns of Patients Treated with Emapalumab for Primary Hemophagocytic Lymphohistiocytosis in the United States: The Real-HLH Study
    Allen, Carl E.
    Chandrakasan, Shanmuganathan
    Jordan, Michael B.
    Leiding, Jennifer W.
    Oladapo, Abiola
    Pednekar, Priti
    Walkovich, Kelly J.
    Yee, John
    BLOOD, 2022, 140 : 2595 - 2596
  • [27] Safety of Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis: Results of the Primary Analysis of the Pivotal Phase 2/3 Study
    Locatelli, Franco
    Jordan, Michael B.
    Allen, Carl
    Cesaro, Simone
    Rizzari, Carmelo
    Rao, Anupama
    Degar, Barbara
    Garrington, Tim
    Sevilla, Julian
    Putti, Maria Caterina
    Fagioli, Franca
    Ahlmann, Martina
    Diaz, Jose-Luis Dapena
    Henry, Michael
    De Benedetti, Fabrizio
    Grom, Alexei
    de Min, Cristina
    BLOOD, 2020, 136
  • [28] CLINICAL CHARACTERISTICS OF PEDIATRIC HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: EXPERIENCES OF 140 PATIENTS WITH HLH IN CHINA
    Zhang, Rui
    Zhang, Li
    Lian, Hong-yun
    Ma, Hong-hao
    Wang, Dong
    PEDIATRIC BLOOD & CANCER, 2015, 62 : S17 - S18
  • [29] REAL-WORLD DEMOGRAPHICS, CLINICAL CHARACTERISTICS, AND TREATMENT PATTERNS OF PATIENTS TREATED WITH EMAPALUMAB FOR HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH) AND NON-HLH CONDITIONS IN THE UNITED STATES: THE REAL-HLH STUDY
    Allen, Carl
    Chandrakasan, Shanmuganathan
    Jordan, Michael B.
    Leiding, JenniferW.
    Oladapo, Abiola
    Pednekar, Priti
    Walkovich, Kelly J.
    Yee, John
    PEDIATRIC BLOOD & CANCER, 2023, 70 : S3 - S3
  • [30] An Adaptive Design Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients with Non-Primary Hemophagocytic Lymphohistiocytosis
    Asnaghi, Veronica
    Ballabio, Maria
    Jacqmin, Philippe
    de Graaf, Kathy
    De Min, Cristina
    BLOOD, 2019, 134
12345